Trial · NCT07898371
A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world Setting
NCT07898371, Recruiting, Sanofi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world Setting. Trials, record NCT07898371. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898371
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world Setting
- NCT number
- NCT07898371
- Status
- Recruiting
- Enrollment
- 3,000 participants, estimated
- Lead sponsor
- Sanofi
- Conditions
- Multiple Sclerosis
- Interventions
- Tolebrutinib
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Socio-demographic Characteristics | Baseline | Number and percentage of participants with socio-demographic characteristics including age, gender, occupational status will be collected. |
| Primary | Disease History: Most Recent Disability Status Scale (EDSS) score | Baseline | Disease history including EDSS score will be collected. The EDSS is a clinician-rated scale, ranging from 0 (normal neurological status) and 10 (death due to MS). Patients with EDSS score up to 4.5 are fully ambulant. Up to this point, the main determinant of EDSS are functional systems (FS), the ambulation status is the main determinant in the degree of disability after 4.5. |
| Primary | Disease History: EDSS Progression in Past 12 Months | Baseline | Disease history including EDSS progression in past 12 Months will be collected. The EDSS is a clinician-rated scale, ranging from 0 (normal neurological status) and 10 (death due to MS). Patients with EDSS score up to 4.5 are fully ambulant. Up to this point, the main determinant of EDSS are functional systems (FS), the ambulation status is the main determinant in the degree of disability after 4.5. |
| Primary | Disease History: Time Since Relapsing-Remitting Multiple Sclerosis (RRMS) Symptom Onset | Baseline | Disease history including time (in years) since RRMS symptom onset will be collected. |
| Primary | Disease History: Time Since Secondary Progressive Multiple Sclerosis (SPMS) Diagnosis | Baseline | Disease history including time (in years) since SPMS diagnosis will be collected. |
| Primary | Disease History: Time Since Most Recent Clinical Relapse | Baseline | Disease history including time (in years) since most recent clinical relapse will be collected. |
| Primary | Disease History: Number and Type of Previous MS Treatments | Baseline | Disease history including number and type of previous MS treatments will be collected. |
| Primary | Disease History: Number and Type of Prior and Current Disease Modifying Therapies (DMTs) | Baseline | Disease history including number and type prior and current DMTs will be collected. |
| Primary | Disease History: Number of Participants with Comorbidities | Baseline | Disease history including comorbidities will be collected. |
| Primary | Disease History: Number of Participants with Medical History | Baseline | Disease history including medical history will be collected. |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Symbol Coding | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898371
GET https://conductscience.org/api/trials/v1/NCT07898371/registered?page=2